What we’re about
Welcome to our AI on Protein and Small Molecule for Drug Discovery group where we explore cutting-edge research and novel AI techniques that can shorten the duration of drug discovery in the pharmaceutical and biotechnology industries.
Specifically, our group provides a hub where technical and business experts from Pharma and Biotech meet AI researchers, StartUps and students in the field of Bioinformatics and Machine Learning — to discuss new trends, work in progress and successful novel AI (industrial and research) works around Protein and Small Molecule.
This group aspires that such AI exchanges would help accelerate the process of Drug Discovery with AI. Join us to connect with like-minded individuals who are interested in new advanced AI technologies or approaches to uncover patterns and complex interconnections between Proteins, Ligands and Chemicals.
Upcoming events (1)
See all- Genome Modeling, Protein Synthesis using AI and Safety in Drug DiscoveryLuise-Ullrich-Straße 14, 80636 Munich, Munich
Hello Everyone,
We would like to invite you to our AI in Pharma MeetUp event that would focus on generative AI in Genome, Protein and Safety in Drug Discovery.
Save the date (23 September 2025) for this AI in Biochemistry MeetUp event in Munich (Address: Luise-Ullrich-Straße 14, 80636 Munich).Thanks to our co-sponsor: Reply Concept
Agenda Overview:
6:30 PM - Door Open, Drinks & Networking7:00 PM - Welcome Introduction
7:05 PM - Talk 1: Genome modeling and design across all domains of life with Evo 2
Garyk Brixi
Genetics PhD Student, Machine Learning for Biology
Stanford University / Arc Institute / Evo 2 Team7:35 PM - Talk 2: From Discovery to Safety: BSL BIOSERVICE Munich - Integrated Approach & Novel Anaphylactic Shock Model
Dr. Robert Torka
Head of Business Development
BSL BIOSERVICE Scientific Laboratories Munich8:05 PM - Drinks, Snacks & Networking
Talks Details:
Talk 1
Title: Genome modeling and design across all domains of life with Evo 2 (Remote Presentation)Abstract:
All of life encodes information with DNA. While tools for sequencing, synthesis, and editing of genomic code have transformed biological research, intelligently composing new biological systems would also require a deep understanding of the immense complexity encoded by genomes. We introduce Evo 2, a biological foundation model trained on 9.3 trillion DNA base pairs from a highly curated genomic atlas spanning all domains of life. We train Evo 2 with 7B and 40B parameters to have an unprecedented 1 million token context window with single-nucleotide resolution. Evo 2 learns from DNA sequence alone to accurately predict the functional impacts of genetic variation—from noncoding pathogenic mutations to clinically significant BRCA1 variants—without task-specific finetuning. Applying mechanistic interpretability analyses, we reveal that Evo 2 autonomously learns a breadth of biological features, including exon–intron boundaries, transcription factor binding sites, protein structural elements, and prophage genomic regions. Beyond its predictive capabilities, Evo 2 generates mitochondrial, prokaryotic, and eukaryotic sequences at genome scale with greater naturalness and coherence than previous methods. Guiding Evo 2 via inference-time search enables controllable generation of epigenomic structure, for which we demonstrate the first inference-time scaling results in biology. We make Evo 2 fully open, including model parameters, training code, inference code, and the OpenGenome2 dataset, to accelerate the exploration and design of biological complexity.Speaker:
Garyk Brixi, Genetics PhD Student
Stanford University / Arc Institute / Evo 2 TeamBiography:
Practical Application:
Designing Protein from generative AI DNA sequences using Evo 2 Foundational Model
https://build.nvidia.com/nvidia/evo2-protein-designAdditional Information:
In addition to Stanford University and Arc Institute, the research was jointly done with researchers from the following institutions:
NVIDIA, OpenAI, Liquid AI, University of California, Berkeley, Goodfire, Columbia University, University of California, San Francisco.Talk 2
Title: From Discovery to Safety: BSL BIOSERVICE Munich - Integrated Approach & Novel Anaphylactic Shock ModelAbstract:
Coming soon.Speaker:
Dr. Robert Torka
Head of Business Development
BSL BIOSERVICE Scientific Laboratories MunichBiography:
Coming Soon.
